Jorge L Yao

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study
    Jorge L Yao
    Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA jorge
    Cancer Invest 27:430-4. 2009
  2. doi Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy
    Koji Izumi
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 43:1991-2000. 2012
  3. ncbi Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54
    Zhiming Yang
    George Whipple Lab for Cancer Research, and University of Rochester Medical Center, Rochester, NY 14642, USA
    Endocrinology 148:1340-9. 2007
  4. doi CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers
    Rochelle A Simon
    Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 40:252-8. 2009
  5. doi GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor
    Hiroshi Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 43:2033-40. 2012
  6. doi Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder
    Hiroshi Miyamoto
    Department of Pathology Urology, University of Rochester Medical Center, Rochester, NY, USA
    BJU Int 109:1716-26. 2012
  7. ncbi Function and molecular mechanisms of neuroendocrine cells in prostate cancer
    Jiaoti Huang
    Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Anal Quant Cytol Histol 29:128-38. 2007
  8. doi Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells
    Yichun Zheng
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Endocr Relat Cancer 18:451-64. 2011
  9. doi Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen
    Koji Izumi
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York
    Mol Carcinog 53:314-24. 2014
  10. ncbi Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth
    Zhiming Yang
    George Whipple Laboratory for Cancer Research, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, New York 14642, USA
    Mol Endocrinol 21:343-58. 2007

Detail Information

Publications23

  1. doi Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study
    Jorge L Yao
    Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA jorge
    Cancer Invest 27:430-4. 2009
    ..001). Our findings reinforce the link between angiogenesis and TF expression in PCa. We suggest further exploration of TF-mediated pathways leading to increased tumor aggressiveness in PCa, and the possible use of anti-TF agents in PCa...
  2. doi Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy
    Koji Izumi
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 43:1991-2000. 2012
    ..093) in nuclear semenogelin I positivity as an independent predictor for recurrence. These results suggest that nuclear semenogelin I expression could be a reliable prognosticator in men who undergo radical prostatectomy...
  3. ncbi Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54
    Zhiming Yang
    George Whipple Lab for Cancer Research, and University of Rochester Medical Center, Rochester, NY 14642, USA
    Endocrinology 148:1340-9. 2007
    ..The novel finding that a protein can modulate AR function without direct interaction with AR might provide a new therapeutic approach to battle prostate cancer by targeting AR indirectly with fewer side effects...
  4. doi CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers
    Rochelle A Simon
    Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 40:252-8. 2009
    ....
  5. doi GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor
    Hiroshi Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 43:2033-40. 2012
    ..Loss of GATA binding protein 3 was associated with high-grade and/or muscle-invasive tumors, whereas strong expression was an independent predictor of poor prognosis...
  6. doi Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder
    Hiroshi Miyamoto
    Department of Pathology Urology, University of Rochester Medical Center, Rochester, NY, USA
    BJU Int 109:1716-26. 2012
    ..Our data demonstrate that the expression status correlates with tumour grades/stages and patients' outcomes...
  7. ncbi Function and molecular mechanisms of neuroendocrine cells in prostate cancer
    Jiaoti Huang
    Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Anal Quant Cytol Histol 29:128-38. 2007
    ..It also discusses molecular pathways involved in NE differentiation and the effectors of the NE cells...
  8. doi Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells
    Yichun Zheng
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Endocr Relat Cancer 18:451-64. 2011
    ..Our results indicate that AR activation upregulates the expression of EGFR and ERBB2 in bladder cancer cells. AR signals may thus contribute to the progression of bladder cancer via regulation of the EGFR/ERBB2 pathways...
  9. doi Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen
    Koji Izumi
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York
    Mol Carcinog 53:314-24. 2014
    ..Moreover, UGT1A is likely regulated by estrogens in non-neoplastic urothelium versus bladder tumor in opposite manners, which could be underlying mechanisms of gender-specific differences in bladder cancer incidence and progression...
  10. ncbi Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth
    Zhiming Yang
    George Whipple Laboratory for Cancer Research, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, New York 14642, USA
    Mol Endocrinol 21:343-58. 2007
    ..The finding that a protein can modulate AR function without direct interaction with AR might provide a new therapeutic approach, with fewer side effects, to battle prostate cancer by targeting AR indirectly...
  11. ncbi Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer
    Chengyu Wu
    Department of Pathology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Prostate 66:1125-35. 2006
    ..Prostate cancer (PC) contains a minor component of neuroendocrine (NE) cells that may stimulate androgen-independent growth of the tumor. The mechanism of neuroendocrine differentiation remains unknown...
  12. pmc Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1
    Aimee M Johnson
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Elmwood Avenue, Rochester, New York, USA
    BMC Urol 8:7. 2008
    ..Furthermore, because BC growth in UPII-SV40T mice is exophytic, we speculated BC growth was dependent on angiogenesis and angiogenesis was, in turn, androgen responsive...
  13. ncbi Immunohistochemical characterization of neuroendocrine cells in prostate cancer
    Jiaoti Huang
    Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Prostate 66:1399-406. 2006
    ..Neuroendocrine (NE) cells increase in high grade/stage prostate cancer (PC) and may contribute to androgen-independent cancer. Their immunohistochemical phenotype has not been studied in detail and conflicting results have been reported...
  14. doi Expression of semenogelins I and II and its prognostic significance in human prostate cancer
    Anastasia M Canacci
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Prostate 71:1108-14. 2011
    ..Little is known about the role of semenogelins, seminal plasma proteins that play critical roles in semen clotting and subsequent liquefaction in the presence of zinc and prostate-specific antigen, in human malignancies...
  15. pmc Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer
    Jiaoti Huang
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Box 626, Rochester, NY 14642, USA
    Am J Pathol 166:1807-15. 2005
    ....
  16. doi Frozen section assessment in testicular and paratesticular lesions suspicious for malignancy: its role in preventing unnecessary orchiectomy
    M Kristina Subik
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 43:1514-9. 2012
    ....
  17. doi Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens
    Jennifer Gordetsky
    Department of Pathology, University of Rochester, Rochester, NY 14642, USA
    Mod Pathol 25:140-4. 2012
    ..However, as none of the additional lymph nodes contained metastatic disease, it is unclear if there is a clinical benefit in evaluating lymph nodes that are neither visible nor palpable in lymphadenectomy specimens...
  18. doi Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors
    Lin Li
    Department of Pathology, University of Rochester Medical Center, Box 626, Rochester, NY 14642, USA
    Hum Pathol 39:1205-11. 2008
    ..Immunohistochemical detection of the combined expression of IMP3 and p53 is useful in the diagnosis of high-grade urothelial tumors, particularly in small, superficial materials...
  19. ncbi Influence of histologic criteria and confounding factors in staging equivocal cases for microscopic perivesical tissue invasion (pT3a): an interobserver study among genitourinary pathologists
    Vijayalakshmi Ananthanarayanan
    Department of Pathology, University of Chicago, Chicago, IL Department of Biostatistics and Bioinformatics, Rollins School of Public Health Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN Department of Pathology, Johns Hopkins Hospital, Baltimore, MD Department of Pathology, University of California, San Diego, CA Division of Anatomic Pathology, Mayo Clinic, Rochester, MN Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH Department of Pathology, Massachusetts General Hospital, Boston, MA Department of Pathology, MD Anderson Cancer Center Department of Pathology, Methodist Hospital, Houston, TX Department of Pathology, Memorial Sloan Kettering Cancer Center, New York Department of Pathology, University of Rochester Medical Center, Rochester, NY Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada Department of Pathology, Nagoya Daini Red Cross Hospital, Nagoya
    Am J Surg Pathol 38:167-75. 2014
    ..This study highlights the need to adopt common criteria in defining the outer MP boundary. Future studies may identify the most clinically relevant histoanatomic criteria for MPVTI. ..
  20. pmc Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experience
    Jennifer Gordetsky
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY Department of Urology, University of Rochester Medical Center, Rochester, New York, USA
    Can Urol Assoc J 5:E47-51. 2011
    ..Very little is known about the role of frozen section analysis (FSA) for these lesions in terms of intraoperative surgical management...
  21. doi Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung
    Jiqing Ye
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Appl Immunohistochem Mol Morphol 19:313-7. 2011
    ....
  22. ncbi Small cell carcinoma of the prostate: an immunohistochemical study
    Jorge L Yao
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, and Department of Pathology, Rochester General Hospital, Rochester, NY 14642, USA
    Am J Surg Pathol 30:705-12. 2006
    ..Immunohistochemical markers can help separate SCPC from HGPC and may be useful in histologically borderline cases. Potential therapeutic targets are identified immunohistochemically in SCPC (Bombesin/GRP, c-kit, bcl-2, and EGFR)...
  23. ncbi Frequent expression of human carcinoma-associated antigen, a mucin-type glycoprotein, in cells of prostatic carcinoma
    Rongshan Li
    Department of Pathology, University of Rochester, Rochester, NY 14642, USA
    Arch Pathol Lab Med 128:1412-7. 2004
    ..However, to our knowledge, expression of HCA in benign and neoplastic prostatic tissue has not been studied...